Influence of publication of US and European prostate cancer screening trials on PSA testing practices

Steven B. Zeliadt, Richard M. Hoffman, Ruth Etzioni, John L. Gore, Larry G. Kessler, Daniel W. Lin

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95% confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20% reduction in mortality among the screening group (rate ratio = 0.80, 95% confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly - by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications.

Original languageEnglish (US)
Pages (from-to)520-523
Number of pages4
JournalJournal of the National Cancer Institute
Volume103
Issue number6
DOIs
StatePublished - Mar 16 2011
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Early Detection of Cancer
Publications
Prostatic Neoplasms
Confidence Intervals
Mortality
Urology
Advisory Committees
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Primary Health Care
Outcome Assessment (Health Care)
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Influence of publication of US and European prostate cancer screening trials on PSA testing practices. / Zeliadt, Steven B.; Hoffman, Richard M.; Etzioni, Ruth; Gore, John L.; Kessler, Larry G.; Lin, Daniel W.

In: Journal of the National Cancer Institute, Vol. 103, No. 6, 16.03.2011, p. 520-523.

Research output: Contribution to journalArticle

Zeliadt, Steven B. ; Hoffman, Richard M. ; Etzioni, Ruth ; Gore, John L. ; Kessler, Larry G. ; Lin, Daniel W. / Influence of publication of US and European prostate cancer screening trials on PSA testing practices. In: Journal of the National Cancer Institute. 2011 ; Vol. 103, No. 6. pp. 520-523.
@article{75b13d3ebc74413fa205a6c97544e79f,
title = "Influence of publication of US and European prostate cancer screening trials on PSA testing practices",
abstract = "In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95{\%} confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20{\%} reduction in mortality among the screening group (rate ratio = 0.80, 95{\%} confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly - by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications.",
author = "Zeliadt, {Steven B.} and Hoffman, {Richard M.} and Ruth Etzioni and Gore, {John L.} and Kessler, {Larry G.} and Lin, {Daniel W.}",
year = "2011",
month = "3",
day = "16",
doi = "10.1093/jnci/djr007",
language = "English (US)",
volume = "103",
pages = "520--523",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Influence of publication of US and European prostate cancer screening trials on PSA testing practices

AU - Zeliadt, Steven B.

AU - Hoffman, Richard M.

AU - Etzioni, Ruth

AU - Gore, John L.

AU - Kessler, Larry G.

AU - Lin, Daniel W.

PY - 2011/3/16

Y1 - 2011/3/16

N2 - In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95% confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20% reduction in mortality among the screening group (rate ratio = 0.80, 95% confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly - by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications.

AB - In 2009, results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial indicated no difference in mortality between the screening and the control groups (rate ratio = 1.13, 95% confidence interval = 0.75 to 1.70), whereas those from the European Randomized study of Screening for Prostate Cancer trial indicated a 20% reduction in mortality among the screening group (rate ratio = 0.80, 95% confidence interval = 0.65 to 0.98). In this study, we examined whether prostate-specific antigen (PSA) testing has changed following these publications. The primary outcome measure was the proportion of men seen at least once in a primary care or urology clinic between August 1, 2004, and March 31, 2010, who received a PSA test. Following the publications, PSA use declined slightly - by 3.0 percentage points and 2.7 percentage points among men aged 40-54 and 55-74 years, respectively. PSA testing among men older than 75 years initially declined slightly following the recommendations by the US Preventive Services Task Force in 2008 and continued to decline after the trial publications.

UR - http://www.scopus.com/inward/record.url?scp=79952846678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952846678&partnerID=8YFLogxK

U2 - 10.1093/jnci/djr007

DO - 10.1093/jnci/djr007

M3 - Article

C2 - 21357307

AN - SCOPUS:79952846678

VL - 103

SP - 520

EP - 523

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -